Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Neuropharmacology
2016 Mar 01;102:158-73. doi: 10.1016/j.neuropharm.2015.11.004.
Show Gene links
Show Anatomy links
Distinctive effects of nicotinic receptor intracellular-loop mutations associated with nocturnal frontal lobe epilepsy.
Weltzin MM
,
Lindstrom JM
,
Lukas RJ
,
Whiteaker P
.
???displayArticle.abstract???
Previously characterized nicotinic acetylcholine receptor (nAChR) autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE)-associated mutations are found in α2, α4 and β2 subunit transmembrane (TM) domains. They predominantly increase ACh potency and, for β2-subunit mutants, increase macroscopic currents. Two recently-identified mutations, α4(R336H) and β2(V337G), located in the intracellular cytoplasmic loop (C2) have been associated with non-familial NFLE. Effects of these mutations on α4β2-nAChR function and expression were studied for the first time, using two-electrode voltage clamp recordings in Xenopus laevis oocytes. Biased-ratio preparations elucidated the mutations' effects at alternate isoforms: high-sensitivity [HS; (α4)2(β2)3] or low-sensitivity [LS; (α4)3(β2)2] via 1:10 or 30:1 [α4:β2] cRNA injection ratios, respectively. An unbiased (1:1 [α4:β2] cRNA) injection ratio was also used to study potential shifts in isoform expression. α4(R336H)-containing receptors showed significant increases in maximal ACh-induced currents (Imax) in all preparations (140% increase compared to wild type control). β2(V337G)-containing receptors significantly increased Imax in the LS-favoring preparation (20% increase compared to control). Expression of either mutation consistently produced enrichment of HS-isoform expression in all preparations. α4β2-nAChR harboring either NFLE mutant subunit showed unchanged ACh, sazetidine-A, nicotine, cytisine and mecamylamine potency. However, both mutant subunits enhanced partial agonist efficacies in the LS-biased preparation. Using β2-subunit-specific [(125)I]mAb 295 immunolabeling, nAChR cell-surface expression was determined. Antibody binding studies revealed that the β2(V337G) mutation tended to reduce cell-surface expression, and function per receptor was significantly increased by either NFLE mutant subunit in HS-favoring preparations. These findings identify both common and differing features between TM- and C2-domain AD/NFLE-associated mutations. As we discuss, the shared features may be particularly salient to AD/NFLE etiology.
Bertrand,
How mutations in the nAChRs can cause ADNFLE epilepsy.
2002, Pubmed,
Xenbase
Bertrand,
How mutations in the nAChRs can cause ADNFLE epilepsy.
2002,
Pubmed
,
Xenbase
Bertrand,
The CHRNB2 mutation I312M is associated with epilepsy and distinct memory deficits.
2005,
Pubmed
Briggs,
High- and low-sensitivity subforms of alpha4beta2 and alpha3beta2 nAChRs.
2006,
Pubmed
Brodtkorb,
Tobacco habits modulate autosomal dominant nocturnal frontal lobe epilepsy.
2006,
Pubmed
Carbone,
Pentameric concatenated (alpha4)(2)(beta2)(3) and (alpha4)(3)(beta2)(2) nicotinic acetylcholine receptors: subunit arrangement determines functional expression.
2009,
Pubmed
,
Xenbase
Chen,
A novel mutation of the nicotinic acetylcholine receptor gene CHRNA4 in sporadic nocturnal frontal lobe epilepsy.
2009,
Pubmed
De Fusco,
The nicotinic receptor beta 2 subunit is mutant in nocturnal frontal lobe epilepsy.
2000,
Pubmed
Eaton,
The unique α4+/-α4 agonist binding site in (α4)3(β2)2 subtype nicotinic acetylcholine receptors permits differential agonist desensitization pharmacology versus the (α4)2(β2)3 subtype.
2014,
Pubmed
,
Xenbase
Figl,
Two mutations linked to nocturnal frontal lobe epilepsy cause use-dependent potentiation of the nicotinic ACh response.
1998,
Pubmed
,
Xenbase
Gotti,
Partial deletion of the nicotinic cholinergic receptor alpha 4 or beta 2 subunit genes changes the acetylcholine sensitivity of receptor-mediated 86Rb+ efflux in cortex and thalamus and alters relative expression of alpha 4 and beta 2 subunits.
2008,
Pubmed
Hales,
Common determinants of single channel conductance within the large cytoplasmic loop of 5-hydroxytryptamine type 3 and alpha4beta2 nicotinic acetylcholine receptors.
2006,
Pubmed
Harpsøe,
Unraveling the high- and low-sensitivity agonist responses of nicotinic acetylcholine receptors.
2011,
Pubmed
Hauser,
Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984.
1993,
Pubmed
Hirose,
A novel mutation of CHRNA4 responsible for autosomal dominant nocturnal frontal lobe epilepsy.
1999,
Pubmed
Hoda,
Human nocturnal frontal lobe epilepsy: pharmocogenomic profiles of pathogenic nicotinic acetylcholine receptor beta-subunit mutations outside the ion channel pore.
2008,
Pubmed
,
Xenbase
Klaassen,
Seizures and enhanced cortical GABAergic inhibition in two mouse models of human autosomal dominant nocturnal frontal lobe epilepsy.
2006,
Pubmed
Kracun,
Influence of the M3-M4 intracellular domain upon nicotinic acetylcholine receptor assembly, targeting and function.
2008,
Pubmed
Kuo,
Roles for nicotinic acetylcholine receptor subunit large cytoplasmic loop sequences in receptor expression and function.
2005,
Pubmed
Kuryatov,
Mutation causing autosomal dominant nocturnal frontal lobe epilepsy alters Ca2+ permeability, conductance, and gating of human alpha4beta2 nicotinic acetylcholine receptors.
1997,
Pubmed
,
Xenbase
Kuryatov,
Expression of functional human α6β2β3* acetylcholine receptors in Xenopus laevis oocytes achieved through subunit chimeras and concatamers.
2011,
Pubmed
,
Xenbase
Lai,
Long-term nicotine treatment decreases striatal alpha 6* nicotinic acetylcholine receptor sites and function in mice.
2005,
Pubmed
Lambe,
Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex.
2003,
Pubmed
Leonardi,
The global burden of epilepsy.
2002,
Pubmed
Liu,
The identification of a novel mutation of nicotinic acetylcholine receptor gene CHRNB2 in a Chinese patient: Its possible implication in non-familial nocturnal frontal lobe epilepsy.
2011,
Pubmed
Lukas,
International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits.
1999,
Pubmed
Marks,
Two pharmacologically distinct components of nicotinic receptor-mediated rubidium efflux in mouse brain require the beta2 subunit.
1999,
Pubmed
Mazzaferro,
Additional acetylcholine (ACh) binding site at alpha4/alpha4 interface of (alpha4beta2)2alpha4 nicotinic receptor influences agonist sensitivity.
2011,
Pubmed
,
Xenbase
McClure-Begley,
Exploring the nicotinic acetylcholine receptor-associated proteome with iTRAQ and transgenic mice.
2013,
Pubmed
Moroni,
alpha4beta2 nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine.
2006,
Pubmed
,
Xenbase
Moroni,
Stoichiometry and pharmacology of two human alpha4beta2 nicotinic receptor types.
2006,
Pubmed
,
Xenbase
Motamedi,
Autosomal dominant nocturnal frontal lobe epilepsy.
2002,
Pubmed
Nelson,
Alternate stoichiometries of alpha4beta2 nicotinic acetylcholine receptors.
2003,
Pubmed
,
Xenbase
Noebels,
Nicotinic acetylcholine receptor mutations
2012,
Pubmed
Phillips,
Localization of a gene for autosomal dominant nocturnal frontal lobe epilepsy to chromosome 20q 13.2.
1995,
Pubmed
Picard,
Alteration of the in vivo nicotinic receptor density in ADNFLE patients: a PET study.
2006,
Pubmed
Pollock,
Cyclic AMP-dependent protein kinase A and protein kinase C phosphorylate alpha4beta2 nicotinic receptor subunits at distinct stages of receptor formation and maturation.
2009,
Pubmed
Provini,
Nocturnal frontal lobe epilepsy. A clinical and polygraphic overview of 100 consecutive cases.
1999,
Pubmed
Rodrigues-Pinguet,
Five ADNFLE mutations reduce the Ca2+ dependence of the mammalian alpha4beta2 acetylcholine response.
2003,
Pubmed
,
Xenbase
Rodrigues-Pinguet,
Mutations linked to autosomal dominant nocturnal frontal lobe epilepsy affect allosteric Ca2+ activation of the alpha 4 beta 2 nicotinic acetylcholine receptor.
2005,
Pubmed
,
Xenbase
Scheffer,
Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder.
1995,
Pubmed
Scheffer,
Autosomal dominant frontal epilepsy misdiagnosed as sleep disorder.
1994,
Pubmed
Son,
Nicotine normalizes intracellular subunit stoichiometry of nicotinic receptors carrying mutations linked to autosomal dominant nocturnal frontal lobe epilepsy.
2009,
Pubmed
Steinlein,
Mutations in familial nocturnal frontal lobe epilepsy might be associated with distinct neurological phenotypes.
2012,
Pubmed
Steinlein,
Animal models for autosomal dominant frontal lobe epilepsy: on the origin of seizures.
2010,
Pubmed
,
Xenbase
Steinlein,
Genetic mechanisms that underlie epilepsy.
2004,
Pubmed
Steinlein,
A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy.
1995,
Pubmed
Steinlein,
An insertion mutation of the CHRNA4 gene in a family with autosomal dominant nocturnal frontal lobe epilepsy.
1997,
Pubmed
Stokes,
Looking below the surface of nicotinic acetylcholine receptors.
2015,
Pubmed
Taly,
Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system.
2009,
Pubmed
Tapia,
Ca2+ permeability of the (alpha4)3(beta2)2 stoichiometry greatly exceeds that of (alpha4)2(beta2)3 human acetylcholine receptors.
2007,
Pubmed
,
Xenbase
Tsetlin,
Assembly of nicotinic and other Cys-loop receptors.
2011,
Pubmed
Unwin,
Refined structure of the nicotinic acetylcholine receptor at 4A resolution.
2005,
Pubmed
Weiland,
An amino acid exchange in the second transmembrane segment of a neuronal nicotinic receptor causes partial epilepsy by altering its desensitization kinetics.
1996,
Pubmed
,
Xenbase
Whiteaker,
Immunolabeling demonstrates the interdependence of mouse brain alpha4 and beta2 nicotinic acetylcholine receptor subunit expression.
2006,
Pubmed
Whiteaker,
Pharmacological and immunochemical characterization of alpha2* nicotinic acetylcholine receptors (nAChRs) in mouse brain.
2009,
Pubmed
Whiting,
Characterization of bovine and human neuronal nicotinic acetylcholine receptors using monoclonal antibodies.
1988,
Pubmed
Willoughby,
Nicotine as an antiepileptic agent in ADNFLE: an N-of-one study.
2003,
Pubmed
Xiao,
Sazetidine-A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them.
2006,
Pubmed
Zwart,
Four pharmacologically distinct subtypes of alpha4beta2 nicotinic acetylcholine receptor expressed in Xenopus laevis oocytes.
1998,
Pubmed
,
Xenbase
Zwart,
Sazetidine-A is a potent and selective agonist at native and recombinant alpha 4 beta 2 nicotinic acetylcholine receptors.
2008,
Pubmed
,
Xenbase
